Bristol-Myers Squibb has announced its financial results for 2017, during which it generated full-year revenues of $20.8 billion (GBP 14.97 billion).
This represented a year-on-year increase of seven percent, with fourth-quarter revenues of $5.4 billion - up by four percent on Q4 2016 - contributing strongly to this performance.
“Bristol-Myers Squibb has reported strong financial results for 2017, thanks to robust sales of products such as Opdivo and Eliquis.“
During the year, the company achieved robust sales for key products such as Opdivo and Eliquis, while reporting a number of important clinical and regulatory milestones in its oncology programme.
In particular, the firm's Opdivo plus Yervoy combination was accepted for US and EU review as a treatment for renal cell carcinoma, with Opdivo studies also showing its effectiveness in the treatment of non-small cell lung cancer and resected melanoma.
For 2018, the company expects its worldwide revenues to increase in the low to mid-single-digit range.
Dr Giovanni Caforio, chairman and chief executive officer of Bristol-Myers Squibb, said: "I am proud of our results in 2017, with sales growth driven by strong commercial performance of our prioritised brands and important scientific advances we are making across our pipeline."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical